Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Gene signature links to drug target

An analysis of hundreds of breast tumours has revealed a way to target a class with poor prognosis.

Overexpression of the protein ERRα has been linked to poor clinical outcomes in patients with breast cancer. Donald McDonnell at Duke University in Durham, North Carolina, and his colleagues analysed gene expression in more than 800 breast tumours, and found that the expression of a cluster of co-regulated genes correlated with both higher ERRα activity and shorter relapse-free survival. Follow-up in 17 tumour cell lines showed that tumours with increased expression of this gene cluster were also more sensitive to a compound called XCT790, which blocks ERRα signalling.

Reducing the expression of another protein, PGC1β, an important cofactor for ERRα, also reduced ERRα signalling and cell proliferation.

Cancer Cell 10.1016/j.ccr.2011.08.023 (2011)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gene signature links to drug target. Nature 478, 289 (2011).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing